Description

Accomplished biotech leader and consultant with proven track record from global strategy through development/operations to partnering and commercialisation and company financing. Hands-on experience in all stages of the pharmaceutical and biotech industry value chain including registrations in EU, US, CA, JP for antibodies and microbial peptides/proteins especially with biosimilars. First-hand experience with nanotechnology, innovative antibodies, complex generics, diagnostics and delivery devices. Experience with CDMO business as provider and customer. Broad therapeutic area expertise from immunology to oncology, including hematological malignancies, solid tumors, dermatology, MS, RA, T1D, asthma, opththalmology, nephrology, orphan diseases.

Languages

German
Native or bilingual
English
Fluent
French
Conversational
Italian
Basic

Workplace preferences

Can work on-site

Munich (up to 50km)

Martin Biotech Consulting
Independent Consultant
BIOTECH
January 2023 - Today (3 years and 5 months)
Munich, BY, Germany
Supporting investors and clients in the global pharmaceutical and biotech industries with interim management, valuations, due diligence, business strategy, operations management, start-up activities, drug development, BD&L, partnering, alliance management and financing in the areas of innovative biotechnology, biosimilars and generics.
Topas Therapeutics GmbH
Chief Executive Officer
August 2020 - December 2022 (2 years and 4 months)
Hamburg, Germany
Growing a leading player in antigen-specific immune tolerance to treat autoimmune diseases, allergies and anti-drug immune responses. Build a leading team. Fundraising with VCs. Build a platform technology and progress clinical-stage pipeline.
Apotex Inc.
President, Apobiologix
January 2018 - May 2020 (2 years and 4 months)
Toronto, ON, Canada
Leading Apotex biologics division, focusing on the development and commercialisation of oncology biosimilars and complex generics in North America and other global markets. Member of Apotex Global Executive Committee.